Biotech takes aim at large anti-estrogen markets

Abstract

Next year, San Diego–based Ligand Pharmaceuticals is hoping to launch a thirdgeneration selective estrogen receptor modulator (SERM) that it developed with Wyeth of Collegeville, Pennsylvania. The company is among as many as two dozen around the world who believe they can hit a home run in the race to develop the next generation of SERM drugs. Most are… (More)
DOI: 10.1038/nbt1206-1455

Topics

1 Figure or Table

Slides referencing similar topics